Showing posts with label ecdc. Show all posts
Showing posts with label ecdc. Show all posts

Friday, August 7, 2026

Seasonal #surveillance in #humans in 2026 for West Nile virus in #Europe (#WNV) (ECDC, August 7 '26): 241 cases so far of which 139 in #Italy

 


{Excerpt}

Week 32, 2026Produced on 7 August 2026 at 10:00, based on data submitted up until and including 5 August 2026.


Current situation

    Since the beginning of the 2026 transmission season, and as at 5 August, 59 areas affected by West Nile virus (WNV) have been identified in seven countries across Europe.

    These areas are located in: 

        § Italy (36), 

        § Greece (nine), 

        § Romania (six), 

        § North Macedonia (three), 

        § France (two), 

        § Spain (two) and 

        § Germany (one).

    The seven countries have reported 241 locally acquired human cases of WNV infection: 

        § Italy has reported 139

        § Greece 61

        § Spain 17

        § North Macedonia 13

        § Romania six

        § France four and 

        § Germany one case.

    This week, 10 areas are reported as affected for the first time this season. The affected areas identified as at 5 August 2026 are listed in Table 1 and shown in Map 1 below.

(...)


{WNV Affected Areas - Click on Image to Enlarge}

__


Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, July 31, 2026

Seasonal #surveillance in #humans in 2026 for West Nile virus (#WNV) (ECDC, July 31 '26): 158 cases so far of which 94 from #Italy

 


{Summary}

Week 31, 2026 | Produced on 30 July 2026 at 12:00, based on data submitted up until and including 29 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 29 July, 49 areas affected by West Nile virus (WNV) have been identified in seven countries across Europe.

    ° These areas are located in: 

        § Italy (30), 

        § Greece (eight), 

        § Romania (four), 

        § France (two), 

        § North Macedonia (two), 

        § Spain (two) and 

        § Germany (one).

    ° The seven countries have reported 158 locally acquired human cases of WNV infection: 

        § Italy has reported 94

        § Greece 42

        § North Macedonia seven

        § Spain seven

        § Romania five

        § France two and 

        § Germany one case.

    ° This week, 14 areas are reported as affected for the first time this season. The affected areas identified as at 29 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)


{Click on Image to Enlarge}

__

{In Yellow, areas already affected since the beginning of the season.}

{In Red, areas newly affected this week.}

__

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, July 24, 2026

Seasonal #surveillance in #humans in 2026 for #WNV (West Nile Virus) (ECDC, July 24 '26): 81 confirmed cases so far of which 46 in #Italy

 


{Excerpt}

Week 30, 2026Produced on 23 July 2026 at 09:45, based on data submitted up until and including 22 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 22 July, 35 areas affected by West Nile virus (WNV) have been identified in six countries across Europe.

    ° These areas are located in: 

        § Italy (20), 

        § Greece (six), 

        § Romania (four), 

        § North Macedonia (two), 

        § Spain (two) and 

        § France (one).


    ° The six countries have reported 81 locally acquired human cases of WNV infection: 

        § Italy has reported 46

        § Greece 21

        § North Macedonia five

        § Romania five

        § Spain three and 

        § France one case.


    ° This week, nine areas are reported as affected for the first time this season. The affected areas identified as at 22 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)


Table 1. Areas affected by West Nile virus during the 2026 transmission season at 22 July, by country and NUTS3 or GAUL1 area




{Click on Images to Enlarge}

(...)


____

Friday, July 17, 2026

#WNV in #humans, the European Region, Weekly #Report (ECDC, July 17 '26): #Italy (21), #Greece (7), North #Macedonia (2), #Romania (2) & #Spain (2) cases so far

 


{Excerpt}

Week 29, 2026Produced on 17 July 2026 at 08:30, based on data submitted up until and including 15 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 15 July, 28 areas affected by West Nile virus (WNV) have been identified in five countries across Europe {1}.

    ° These areas are located in: 

        § Italy (17), 

        § Greece (five), 

        § North Macedonia (two), 

       § Romania (two) and 

        § Spain (two).

    ° The five countries have reported 34 locally acquired {2} human cases of WNV infection

        § Italy has reported 21

        § Greece seven,     

        § North Macedonia two

        § Romania two and 

        § Spain two cases.

    ° This week, 17 areas are reported as affected for the first time this season. The affected areas identified as at 15 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)

Table 1. Areas affected by West Nile virus during the 2026 transmission season at 15 July, by country and NUTS3 or GAUL1 area



{Click on Images to Enlarge}

__

* ‘First reported this week’ indicates that the affected area was not included in the previous weekly overview.

(...)

Source: 


____


Friday, July 10, 2026

Seasonal #surveillance in #humans in 2026 for #WNV - Update (ECDC, July 10 '26): #Italy reported 6 cases, #Macedonia 2, #Romania 2, #Greece 1, #Spain 1

 


Week 28, 2026Produced on 9 July 2026 at 08:45, based on data submitted up to 8 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as of 8 July, 11 areas affected by West Nile virus (WNV) have been identified in five countries across Europe {1}.

    ° These areas are located in: 

        - Italy (five), 

        - North Macedonia (two), 

        - Romania (two), 

        - Greece (one) and 

        - Spain (one).

    ° The five countries have reported 12 locally acquired {2} human cases of WNV infection: 

        - Italy has reported six, 

        - North Macedonia two, 

        - Romania two, 

        - Greece one and 

        - Spain one case.

    ° This week, five areas are reported as affected for the first time this season. 

(...)


Table 1. Areas affected by West Nile virus during the 2026 transmission season as of 8 July, by country and NUTS3 or GAUL1 area


{Click on Image to Enlarge}

(...)

__

{*} ‘First reported this week’ indicates that the affected area was not included in the previous weekly overview.

{1} European Union/European Economic Area countries and selected EU-neighbouring countries (Albania, Bosnia and Herzegovina, Kosovo**, Montenegro, North Macedonia, Serbia and TĂ¼rkiye).

{**} This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.↩︎

{2} Cases acquired within the reporting country.↩︎

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Saturday, July 4, 2026

Seasonal #surveillance in #humans in 2026 for #WNV - Weekly Report (ECDC, Week 27, 2026, July 4 '26): Six cases reportes so far in total {#Italy, #Romania, N. #Macedonia}

 


Week 27, 2026

Produced on 2 July 2026 at 12:00 based on data submitted up to 1 July 2026


Epidemiological summary

    Since the beginning of 2026, and as of 1 July, three countries in Europe reported six human cases{1} of West Nile virus (WNV) infection: Italy (three cases), Romania (two cases) and North Macedonia (one case).

    The current report in Table 1 includes the number of probable and confirmed cases of WNV infections per NUTS3 region. However, these figures are preliminary and should be interpreted with caution as they may be revised by the countries as more information becomes available. 

    For further details on case numbers, please refer to the joint monthly report, which offers a more detailed analysis.

    Please note: The table and map in this report contain countries and areas where human West Nile virus infection cases were reported to EpiPulse Cases.

(...)


Overview of West Nile virus cases in EU/EEA and EU-neighbouring countries

Table 1. Countries and regions with locally acquired human cases of West Nile virus infections in 2026 as of 1 July.


{Click on Image to Enlarge}

* An ‘affected area’ or ‘risk area’ is defined as ‘a risk area with ongoing transmission of WNV to humans’. This means that at least one autochthonous human case of WNV has been reported as a result of local transmission in the area according to the agreed, standardised and disease-specific case definition. In exceptional circumstances, a probable case can be used to determine transmission, however, this should only apply in specific and agreed situations when a case cannot be confirmed within a reasonable time.


** Compared to the previous weekly report.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Wednesday, July 1, 2026

Seasonal #surveillance in #humans and #animals in 2026 for West Nile virus (#WNV) (ECDC, Monthly Report, Summary)

 


June 2026 | Produced on 30 June 2026 at 07:15 based on data submitted up to 24 June 2026


Epidemiological summary

    As of 24 June, two countries in Europe reported three locally acquired1 human cases of WNV infection

        ° Italy reported two cases and 

        ° North Macedonia one case

    Dates of onset ranged from 12 to 27 May 2026

    No deaths have been reported.

    The cases were reported from three regions across the two countries. Although no cases had been reported by this time in 2025, some cases with onset dates in May and June were subsequently notified with a delay. Therefore, the current situation remains consistent with the early phase of the seasonal reporting pattern observed in previous years.

    This year, human cases of WNV infection were reported for the first time ever in one affected area: North Macedonia in Vardarski (MK001).

    Among the three cases reported this year, one person was aged 65 years or older, one was aged under 65 years, and the age of one person was unknown. All three cases were hospitalised

    Neurological manifestations were reported in two individuals; information on clinical presentation was unavailable for the remaining case. 

    As only three cases have been reported to date, comparisons with demographic or severity patterns observed over the previous decade are not yet meaningful. Further updates will be provided in subsequent monthly reports.

    From the veterinary perspective, five WNV outbreaks have been reported in Europe in 2026: one among equids and four among birds

    The equid outbreak was reported by France and started on 30 March 2026. The four bird outbreaks were reported by Italy, with start dates ranging from 31 March to 4 May 2026.

    No information was available on the equid species involved in the outbreak reported in France in the Animal Disease Information System (ADIS). For birds, species information indicated that the four outbreaks reported in Italy involved hooded crows (three outbreaks) and a golden eagle (one outbreak).

    Outbreaks in birds and/or equids have been reported in three regions across two countries. Both countries that reported outbreaks in 2026 had previously reported WNV outbreaks in birds and/or equids in the same regions, indicating that WNV is endemic in these areas.

    The number of outbreaks in birds and equids reported during this first period of 2026 is similar to the mean monthly outbreak count for the same time of year, calculated for 2022–2025 for birds and for 2016–2025 for equids.

    Italy reported both locally acquired human WNV cases and WNV outbreaks in birds; however, the human cases and bird outbreaks were reported from different regions.

    Owing to delays in diagnosis and reporting, and because most WNV infections are asymptomatic or subclinical, the reported case numbers likely underestimate the true number of infections. Seasonal surveillance in humans primarily captures laboratory-confirmed cases, which may further contribute to reporting delays.

    Given the favourable weather conditions for WNV transmission in Europe, ECDC and EFSA expect further human cases and outbreaks in equids and birds to be reported in the coming weeks and months. In previous years, transmission has typically peaked in August and September.

    ECDC and EFSA will continue to closely monitor the situation in Europe.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/infectious-disease-topics/west-nile-virus-infection/surveillance-and-disease-data/monthly-updates

____

Monday, June 29, 2026

#Fact-finding #mission on #airport exit #screening - EU Health Task Force mission to #DRC and #Uganda, #Bundibugyo virus disease #outbreak 2026 (ECDC, summary)

 


Executive summary

    This report provides a snapshot of the infrastructure and procedures in place for exit screening in the main international airports of each capital city: N’djili International Airport in Kinshasa (DRC) and Entebbe International Airport in Kampala (Uganda). 

    Exit screening in these airports, including symptom checks and exposure assessment, can contribute to reducing the risk of onward transmission by identifying travellers who are symptomatic before they board, and preventing them travelling with symptoms. 

    It also helps dissuade people who are ill from travelling, and enhances public and stakeholder confidence in the public health response. 

    However, it cannot fully prevent the exportation of cases, as the absence of symptoms at departure does not exclude subsequent onset of disease upon or after arrival. 

    The mission team found that both countries have established coordinated exit screening systems, supported by strong political commitment and national leadership to prevent international transmission of Ebola disease. 

    These function alongside domestic containment efforts based on extensive experience of managing previous Ebola disease outbreaks. 

    In both countries, the mission team observed a high degree of transparency and willingness to engage with stakeholders through facilitating access to systems and operations. 

    The site visit at both airports demonstrated that the exit screening systems in place are in line with international standards and benefit from effective multi-sectoral collaboration, involving public health authorities, aviation actors, border services, security forces, and international partners. 

    Screening processes have clear referral and escalation pathways supported by trained medical personnel and infection, prevention and control (IPC) measures. 

    While the systems in place are functional, the mission identified opportunities for further targeted interventions, particularly in relation to passenger processing, digital integration, IPC measures and risk communication

    These findings have been communicated to the national authorities in both countries. 

    Regular training, supervision and monitoring over time by national teams and international partners will help to sustain and further improve practices.

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/fact-finding-mission-airport-exit-screening-eu-health-task-force-mission

____

Friday, June 26, 2026

Avian #influenza #overview March–May 2026 (ECDC, Summary, June 26 '26)



26 June 2026

Publication series: Avian influenza overview

    

    Between 28 February and 4 June 2026, 949 highly pathogenic avian influenza (HPAI) A(H5) virus detections were reported in domestic (186) and wild (763) birds in 30 countries in Europe.


Abstract

    The downward trend in the number of detections observed at the end of the previous reporting period continued and is expected to persist throughout the summer. 

    While the number of HPAI A(H5N1) outbreaks in domestic birds remained at a low level, except in a few countries, A(H9N2) virus of clade G5.5 was detected in poultry in Europe for the first time

    Following the intense circulation of HPAI viruses in waterfowl in recent months, sporadic detections were reported in mammals, particularly in wild carnivores, including the detection of A(H5N5) virus in a polar bear and a walrus in Norway

    Outside Europe, the focus of HPAI virus detections shifted from North to South America, where a large number of outbreaks and mortality events in swans were reported. 

    Between 28 February and 4 June 2026, 19 cases of avian influenza virus infection were publicly reported in humans (including three fatal cases) in six countries and territories: Bangladesh (two cases with A(H5N1), one fatal), Cambodia (three cases with A(H5N1), one fatal), India (one case with A(H5N1)), Italy (one imported case with A(H9N2)), China (10 A(H9N2) cases and one fatal A(H5N6) case), and Taiwan (one A(H7N7) case). 

    Most human cases reported exposure to poultry or a poultry environment prior to detection or onset of illness. 

    Human infections with avian influenza viruses remain rare and no sustained human-to-human transmission has been documented. 

    The risk posed by avian influenza A(H5N1) clade 2.3.4.4b viruses currently circulating in Europe remains low for the general public in the European Union/European Economic Area (EU/EEA) and low-to-moderate for those occupationally or otherwise exposed to infected animals or contaminated environments.

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/avian-influenza-overview-march-may-2026

____

Surveillance for West NileVirus Infections in Humans in Europe, Weekly Report: Week 26, 2026 (ECDC, summary)

 


{Excerpt}

Epidemiological summary

    Since the beginning of 2026, and as of 24 June, two countries in Europe reported three human cases{1} of West Nile virus (WNV) infection: Italy (two cases) and North Macedonia (one case).

    The current report in Table 1 includes the number of probable and confirmed cases of WNV infections per NUTS3 region. However, these figures are preliminary and should be interpreted with caution as they may be revised by the countries as more information becomes available. For further details on case numbers, please refer to the joint monthly report, which offers a more detailed analysis.

    Please note: The table and map in this report contain countries and areas where human West Nile virus infection cases were reported to EpiPulse Cases.

(...)

#) Country

    ° Affected area*

        § Newly affected area**

            - Number of probable cases - Number of confirmed cases - Total cases 

1) Italy

    ° Caserta

        § No

            - 0 / 1 /1 

    ° Firenze

         § No

            - 0 / 1 /1 

2) North Macedonia

    ° Vardarski

        § No

            - 0 / 1 / 1

__

{*} An ‘affected area’ or ‘risk area’ is defined as ‘a risk area with ongoing transmission of WNV to humans’. This means that at least one autochthonous human case of WNV has been reported as a result of local transmission in the area according to the agreed, standardised and disease-specific case definition. In exceptional circumstances, a probable case can be used to determine transmission, however, this should only apply in specific and agreed situations when a case cannot be confirmed within a reasonable time.

{**} Compared to the previous weekly report.

(...)

Source: 


Link: https://wnv-weekly.ecdc.europa.eu/

____

Monday, June 22, 2026

#Spain reported a locally acquired Crimean-Congo Hemorrhagic Fever (#CCHF), according latest ECDC report (June 22 '26)

 


(...)

Epidemiological summary

    This is the first report of the weekly seasonal surveillance reports on Crimean-Congo haemorrhagic fever (CCHF) infections in 2026.

    Since the beginning of 2026 and as of 17 June 2026, one country in Europe has reported locally acquired cases of CCHF: 

        ° Spain (one case).

    The case in Salamanca (Spain) is not unexpected as Hyalomma spp. – the main vectors of CCHF virus – are widely distributed across the region. 

    In addition, CCHF virus is known to circulate in local animal populations, and human cases have previously been reported there. 

    The timing of this case aligns with the expected seasonal pattern of CCHF in Spain, and is probably linked to increased tick activity.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/crimean-congo-haemorrhagic-fever/surveillance-and-updates/seasonal

____

Thursday, June 18, 2026

#Surveillance of West Nile Virus {#WNV} #Human #Infections in #Europe, Weekly Report (ECDC, Jun. 18 '26): First two cases reported in #Italy

 


Epidemiological summary

    Since the beginning of 2026, and as of 17 June, 2 countries in Europe reported 3 human cases of West Nile virus infection: Italy and North Macedonia.

    The current report in Table 1 includes the number of probable and confirmed cases of WNV infections per NUTS region. 

    However, these figures are preliminary and should be interpreted with caution as they may be revised by the countries as more information becomes available. 

    Consequently, no totals are provided

    For further details on case numbers, please refer to the joint monthly report, which offers a more detailed analysis.

    Please note: The table and map in this report contain countries and areas where human West Nile virus infection cases were reported to EpiPulse Cases.


Introduction

    The European Centre for Disease Prevention and Control (ECDC) provides a weekly overview of human cases of West Nile virus (WNV) infection to support the competent authorities responsible for blood safety

    This overview can aid decisions on the deferral or testing of blood donors who may have been exposed to the virus, in accordance with Commission Directives 2004/33/EC and 2014/110/EU.

    West Nile virus infection in humans is a notifiable disease at the EU level and cases are reported in accordance with the EU case definition. 

    The table and map in this report show the countries and areas where human cases of WNV infection have been reported to the European surveillance portal for infectious diseases (EpiPulse Cases).

    More information on the occurrence of WNV infection among humans in Europe, as well as WNV outbreaks among equids and birds, is available in the joint monthly report produced by ECDC and the European Food Safety Authority (EFSA).

    Here we present the weekly report as of 17 June 2026.


Overview of West Nile virus cases in EU/EEA and EU-neighbouring countries

Table 1. Countries and regions with locally acquired human cases of West Nile virus infections in 2026 as of 17 June.

[Country

    ° Affected Region

        § Newly Affected Region

           * No. of Probable / Confirmed / Total Cases]

Italy

    ° Caserta

        § Yes

            * 0 / 1 / 1

    ° Firenze

        § Yes

            * 0 / 1 / 1

Macedonia

    ° Vardarski

        § No

            * 0 / 1 / 1

(...)

Source: 


 Link: https://wnv-weekly.ecdc.europa.eu/

____

Wednesday, June 17, 2026

#Andes #hantavirus #outbreak in cruise ship (ECDC, June 17 '26): Some quarantined individuals have left isolation after completing follow-up

 


    On 2 May 2026, ECDC was notified of a cluster of severe respiratory illness on MV Hondius, a Dutch-flagged cruise ship with passengers and crew from 23 countries, including nine EU/EEA countries. 

    The virus has been identified as Andes hantavirus.

    As of 17 June 2026, 13 cases have been reported in total, including 12 confirmed and one probable case.

    As of 17 June 2026, some of the identified contacts associated with the outbreak have completed their quarantine period, while others are expected to do so in the coming days

    Public health authorities continue to monitor the identified contacts however, based on the information currently available, the likelihood of additional cases related to this event is considered very low

    The risk to the general population in the EU/EEA remains very low.


    ° Confirmed cases12

    ° Probable cases1

    ° Suspected cases0

    ° Number of deaths3

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/infectious-disease-topics/hantavirus-infection/surveillance-and-updates/andes-hantavirus-outbreak

____

#Overview of available modelling #evidence to inform the scale and potential spread of #Bundibugyo virus in the current #Ebola disease #outbreak (ECDC, June 17 '26, summary)

 


ASSESSMENT | 17 June 2026


Key findings 

    So far in the current outbreak of Ebola disease caused by Bundibugyo virus, international modelling efforts have focused on estimating the outbreak size and near-term trajectories, as well as the risk of regional and international spread.  

    Multiple modelling groups suggest that the true size of the outbreak is larger than reported

        - One model estimated that cumulative infections as of 13 June were between 3.0 and 10.2 times the reported number of cases (90% credible interval). 

    Epistorm estimated the relative risk of importation to be highest for Rwanda, Tanzania and Kenya, which together account for approximately 54% of the relative risk. 

        - ECDC has estimated the risk of importation into the EU/EEA to be low

    The United States Centers for Disease Control and Prevention published scenario modelling analysis results that estimated a 65% probability that the outbreak will exceed 20 000 cases within three months under a scenario where 20% of individuals with Bundibugyo virus infection were isolated and no other interventions were implemented. 

    Current modelling estimates are highly uncertain due to data limitations. 

        - Multiple epidemic trajectories remain compatible with the available surveillance data, limiting confidence in estimates of outbreak size and future trends. 

(...)

Suggested citation: European Centre for Disease Prevention and Control. Overview of available modelling evidence to inform the scale and potential spread of Bundibugyo virus in the current Ebola disease outbreak. ECDC: Stockholm; 2026.   ISBN 978-92-9498-899-7; doi: 10.2900/3614787; Catalogue number TQ-01-26-044-EN-N 

© European Centre for Disease Prevention and Control, Stockholm, 2026

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/overview-available-modelling-evidence-inform-scale-and-potential-spread

____

Monday, June 15, 2026

Estimation of the #importation #risk of #Bundibugyo virus into the #EU/EEA in June 2026 (ECDC, summary)

 


Assessment | 15 June 2026


    In this report, we present estimates of the probability of importation of Ebola disease caused by Bundibugyo virus (BDBV), into EU/EEA countries for the period 11–25 June 2026 under different assumptions of travel volumes from the areas where most cases were reported from. 

    In addition, we estimate the volume of air travel passengers from this region that would be expected to result in one BDBV importation.


Key findings

    ° The ongoing outbreak of the Bundibugyo virus (BDBV) in the Democratic Republic of the Congo (DRC) has raised some concerns about the BDBV importation risk into the European Union/European Economic Area (EU/EEA).

    ° Based on mathematical modelling, we estimate approximately one importation per 23 000 travellers (90% Uncertainty Interval, UI: 13 000 – 54 000) from the main outbreak region (North Kivu and Ituri, DRC) to the EU/EEA.

    ° We estimate the probability of at least one BDBV importation into the EU/EEA from 11–25 June 2026 to be 0.45% (90% UI: 0.20%-0.85%), under the hypothetical assumption that 100 people travel from the outbreak region to the EU/EEA during this period. 

    ° We consider 100 travellers to be a conservative upper estimate based on available historical flight data and the closure of multiple airports in the proximity of the outbreak region. The true probability of importation is therefore likely to be lower.

    ° These estimates apply to travellers from the general population in the outbreak region. 

    ° The risk of importation associated with returning healthcare workers deployed to support the outbreak response is beyond the scope of this report.


Conclusions

    ° While sporadic BDBV importations into the EU/EEA cannot be ruled out, mathematical modelling suggests that the probability of importation from 11 to 25 June is very low

    ° These results apply to importation of BDBV from the general population of Ituri and North Kivu

    ° Humanitarian aid workers or healthcare care personnel returning from the outbreak region to the EU/EEA, who we assume would be medically evacuated from the affected areas with application of appropriate infection prevention and control measures, need to be considered separately.

    ° As one BDBV importation is expected per 24 000 travellers from the outbreak region, the vast majority of travellers will not be infected

    ° However, since early symptoms of BDBV infections overlap with many other conditions, a potentially large number of travellers will show similar symptoms as BDBV infections without being infected with BDBV (i.e. false positives). 

    ° Therefore, entry screening strategies based solely on symptom detection are likely to have low specificity, which will lead to unnecessary isolation, testing, and follow-up of a potentially large number of individuals per true case.

    ° The presented importation probabilities are model estimates, which are subject to several limitations and are based on currently observed trends of BDBV infections in DRC. 

    ° If there are substantial changes in the epidemiological situation, such as spread to other regions, then the results of this output need to be reassessed.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/estimation-importation-risk-bundibugyo-virus-eueea-june-2026

____

#Risk #classification and contact #tracing of #travellers returning from affected areas – #Ebola disease outbreak 2026 caused by #Bundibugyo virus (ECDC, edited)

 


Public health guidance


    This table and accompanying algorithm provide guidance for EU/EEA public health authorities, decision-makers, and healthcare professionals on risk categorisation and management of individuals potentially exposed to Ebola disease. 

    The guidance applies to contacts of confirmed or probable cases following travel to, residence in, or work in Ebola outbreak-affected areas, as well as to occupational exposures.

    As long as an outbreak is ongoing, individuals arriving from affected regions may develop Ebola disease after entering non-affected countries. Minimising transmission relies on rapid case detection and isolation, effective contact tracing, and strict infection prevention and control (IPC) measures.

    Given the severity of Ebola disease, timely identification and risk-based management of exposed individuals is essential. Early detection of symptomatic contacts enables prompt isolation, testing, and clinical care, thereby reducing the interval between symptom onset and case recognition. This approach minimises opportunities for onward transmission and strengthens outbreak control.


Risk exposure classification and proposed measures

{Risk exposure category

    ° Exposure type and examples

        § Proposed measures}


No exposure

    ° No exposure to symptomatic cases or persons under investigation - E.g. General returning travellers from the affected areas, without any exposure

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival, including targeted behavioural guidance.


Low-risk occupational exposure

    ° Protected occupational exposure*
    E.g. Properly protected (personal protective equipment – PPE - used) contact with suspected/confirmed Ebola disease case, bodily fluids, fomites (e.g. linens), or virus samples (lab specimens, cultures). Doffing of PPE presents an elevated risk of self-contamination if strict measures are not taken to doff PPE per a controlled doffing protocol under the guidance and observation of a trained observer.

    {*} Contact using appropriate PPE is not considered significant exposure, however, context regarding PPE protocols used and their adherence should always be considered.

        § Self- monitoring (passive monitoring) for 21 days after last exposure: temperature and symptoms check twice a day

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.


Low-risk exposure

    ° Contact with symptomatic case (non-fluid exposure) 
    E.g. Close face-to-face contact (e.g. within <1 meter, sharing seating or public transport (incl. airplane), receptionist duties, household/classroom/office contact with a feverish or symptomatic person who has suspected/confirmed Ebola disease not coughing, vomiting, bleeding, or with diarrhoea

        § Self- monitoring (passive monitoring) for 21 days after last exposure: temperature and symptoms check twice a day

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.

        § Public health authorities may indicate more actions, depending on the circumstances 


High-risk exposure

    ° Close contact without appropriate PPE / unprotected exposure
    E.g. Close face-to-face contact (e.g. within <1 meter) or any direct, unprotected or improperly protected contact with a person who has suspected/confirmed Ebola disease, their bodily fluids, contaminated fomites, or infectious laboratory material—particularly when the person is symptomatic (e.g. coughing, vomiting, bleeding, or has diarrhoea)—or direct contact with materials contaminated by bodily fluids, without appropriate personal protective equipment, including eye protection.

    ° Unprotected sexual contact with someone who has Ebola disease or a survivor without confirmed negative semen RT-PCR tests (2 negative tests ≥1 week apart)

    ° Burial exposure 
    E.g. Participation in burial rites with direct contact of the remains or bodily fluids without PPE

    ° Percutaneous injury (e.g. with needle) or mucosal exposure to laboratory specimens suspected of containing orthoebolavirus or to bodily fluids, tissues, or specimens

        § Active monitoring for 21 days following last exposure:

             - Temperature and symptoms check twice a day with active reporting to public health authorities or after active contact by public health authorities

            - Remain reachable

            - No travel abroad

            - Consider restriction of social interactions 

            - Consider restrictions of engagement in clinical activities and follow national occupational health plan

        § Provision of clear, accurate, and up‑to‑date information about Ebola, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.

        § Public health authorities may indicate more actions, depending on the circumstances 

        § In case of clearly established percutaneous injury or mucosal exposure: restrictions of social interactions/contacts and movements as a precautionary measure. 

___

    Other types of ‘high-risk’ exposure are beyond the scope of this document, for example: 

    Direct contact with bushmeat (e.g. eating raw bushmeat, carving up the animal, direct contact with the animal’s blood or bodily fluids), bats, rodents, primates living or dead, in or from Ebola disease-affected areas 

    Exposure through breastfeeding

Note: This classification is based on selected examples of exposures and is not exhaustive. 

(...)

Source: 


____

My New Space

Most Popular Posts